Literature DB >> 31019019

Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia: Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral.

Ammar Asban1, Alex Dombrowsky2, Reema Mallick2, Rongbing Xie3, James K Kirklin3, Raymon H Grogan4, David F Schneider5, Herbert Chen2, Courtney J Balentine6.   

Abstract

BACKGROUND: Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions.
MATERIALS AND METHODS: We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment.
RESULTS: The mean age of the patients was 61 ± 16.5 years, 68% were women, and 55% were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12%), calcium supplements (12%), dehydration (5%), and renal dysfunction (3%). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40% of patients. For 7% of patients, a nonsurgeon stated that surgery offered no benefit; 22% of patients were offered medical treatment or observation, and 8% opted not to see a surgeon. Only 20% of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon.
CONCLUSION: To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease. IMPLICATIONS FOR PRACTICE: This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral. © AlphaMed Press 2019.

Entities:  

Keywords:  Hyperparathyroidism; Parathyroid hormone; Underdiagnosed; Undertreated

Year:  2019        PMID: 31019019      PMCID: PMC6738291          DOI: 10.1634/theoncologist.2018-0424

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  17 in total

1.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

2.  Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial.

Authors:  Anders Bergenfelz; Pia Lindblom; Sten Tibblin; Johan Westerdahl
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Plasma parathyroid hormone is associated with vascular dementia and cerebral hyperintensities in two community-based cohorts.

Authors:  Emil Hagström; Lena Kilander; Ruta Nylander; Elna-Marie Larsson; Karl Michaëlsson; Håkan Melhus; Håkan Ahlström; Lars Johansson; Lars Lind; Johan Arnlöv
Journal:  J Clin Endocrinol Metab       Date:  2014-08-20       Impact factor: 5.958

4.  Improving diagnostic recognition of primary hyperparathyroidism with machine learning.

Authors:  Yash R Somnay; Mark Craven; Kelly L McCoy; Sally E Carty; Tracy S Wang; Caprice C Greenberg; David F Schneider
Journal:  Surgery       Date:  2016-12-15       Impact factor: 3.982

5.  The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record.

Authors:  Danielle M Press; Allan E Siperstein; Eren Berber; Joyce J Shin; Rosemarie Metzger; Rosebel Monteiro; Jeff Mino; Warren Swagel; Jamie C Mitchell
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

6.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

Review 7.  Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction.

Authors:  Kyle A Zanocco; James X Wu; Michael W Yeh
Journal:  Surgery       Date:  2016-11-09       Impact factor: 3.982

8.  Parathyroidectomy, elevated depression scores, and suicidal ideation in patients with primary hyperparathyroidism: results of a prospective multicenter study.

Authors:  Theresia Weber; Julia Eberle; Ursula Messelhäuser; Leif Schiffmann; Christoph Nies; Jochen Schabram; Andreas Zielke; Katharina Holzer; Edit Rottler; Doris Henne-Bruns; Monika Keller; Jörn von Wietersheim
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

9.  Failure to Diagnose Hyperparathyroidism in 10,432 Patients With Hypercalcemia: Opportunities for System-level Intervention to Increase Surgical Referrals and Cure.

Authors:  Courtney J Balentine; Rongbing Xie; James K Kirklin; Herbert Chen
Journal:  Ann Surg       Date:  2017-10       Impact factor: 12.969

10.  A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS).

Authors:  Ning Yu; Peter T Donnan; Graham P Leese
Journal:  Clin Endocrinol (Oxf)       Date:  2011-08       Impact factor: 3.478

View more
  3 in total

1.  ASO Author Reflections: Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons.

Authors:  Courtney Balentine
Journal:  Ann Surg Oncol       Date:  2020-06-15       Impact factor: 5.344

2.  Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study.

Authors:  Yan Yu; Ming Bai; Zhang Wei; Lijuan Zhao; Yangping Li; Feng Ma; Shiren Sun
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

3.  The Arduous Path to Diagnosis in a Patient With a Unique Cause of Gastroesophageal Reflux Disease.

Authors:  Salman Niaz; Sadaf Zia; Laila Tul Qadar; Mahad M Baig; Saad Khalid
Journal:  Cureus       Date:  2022-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.